Naive and Memory B Cell BCR Repertoires in Individuals Immunized with an Inactivated SARS-CoV-2 Vaccine DOI Creative Commons
Renato Kaylan Alves de Oliveira França, Pedro Henrique Aragão Barros,

Jacyelle Medeiros Silva

и другие.

Vaccines, Год журнала: 2025, Номер 13(4), С. 393 - 393

Опубликована: Апрель 8, 2025

The COVID-19 pandemic has spurred a global race for preventive vaccine, with few becoming available just one year after describing this novel coronavirus disease. Among these are inactivated virus vaccines like CoronaVac (Sinovac Biotech), which used in several countries to reduce the pandemic's effects. However, its use was associated low protection, particularly against variants that quickly appeared following months. Vaccines play crucial role activating immune system combat infections, Memory B-cells being key part of mechanism, eliciting protective neutralizing antibodies. This work focused on studying B-cell memory repertoire two consecutive doses CoronaVac. were isolated from five vaccinated and pre-pandemic individuals subsequently stimulated vitro before high-throughput Illumina sequencing Heavy Chain Variable repertoire. We observed shift VH increased HCDR3 length enrichment IGVH 3-23, 3-30, 3-7, 3-72, 3-74 IgA BCRs IGHV 4-39 4-59 IgG BCRs. A high expansion IgA-specific clonal populations relative controls, accompanied by shared variable heavy chain (VH) sequences among B cells across different vaccine recipients clones also compared sharing between vaccines. Moreover, convergence vaccinees SARS-CoV-2 antibody found CoV-abDab database. These data show ability elicit antibodies characteristics similar those previously identified as antibodies, supporting efficacy. Furthermore, analysis immunological context viral infections reinforces importance immunization generating convergent antiviral response.

Язык: Английский

Anti-Spike Mucosal IgA Protection against SARS-CoV-2 Omicron Infection DOI Open Access
Sebastian Havervall, Ulrika Marking,

Julia Svensson

и другие.

New England Journal of Medicine, Год журнала: 2022, Номер 387(14), С. 1333 - 1336

Опубликована: Сен. 14, 2022

nated, 0 to 13 days, 14 27 1 2 months, 3 4 5 6 7 8 or ≥9 months).Among the patients who had received two doses of vaccine, waning effectiveness against hospitalization was evident as early months after vaccination during both periods when omicron sublineages were dominant.The vaccine 56.3% (95% confidence interval [CI], 51.6 60.5) BA.1-BA.2wave and 47.4% CI, 19.9 65.5) BA.4-BA.5 wave (Table 1).Although boosting with a third dose maintained severe disease caused by all four at decreased an 50.0%(95% 4.4 73.9) 46.8% 35.3 56.2) wave.Thus, either three BNT162b2 we found rapid current variant respect protection hospitalization.Our data indicate that maintains sublineages, although evidence durability indicates need for regular last vaccines incorporate variants concern maintain protection.

Язык: Английский

Процитировано

204
Distinct evolution of SARS-CoV-2 Omicron XBB and BA.2.86/JN.1 lineages combining increased fitness and antibody evasion DOI Creative Commons
Delphine Planas, Isabelle Staropoli, Vincent Michel

и другие.

Nature Communications, Год журнала: 2024, Номер 15(1)

Опубликована: Март 13, 2024

Abstract The unceasing circulation of SARS-CoV-2 leads to the continuous emergence novel viral sublineages. Here, we isolate and characterize XBB.1, XBB.1.5, XBB.1.9.1, XBB.1.16.1, EG.5.1.1, EG.5.1.3, XBF, BA.2.86.1 JN.1 variants, representing >80% circulating variants in January 2024. XBB subvariants carry few but recurrent mutations spike, whereas harbor >30 additional changes. These replicate IGROV-1 no longer Vero E6 are not markedly fusogenic. They potently infect nasal epithelial cells, with EG.5.1.3 exhibiting highest fitness. Antivirals remain active. Neutralizing antibody (NAb) responses from vaccinees BA.1/BA.2-infected individuals lower compared BA.1, without major differences between variants. An breakthrough infection enhances NAb against both BA.2.86 displays affinity ACE2 higher immune evasion properties BA.2.86.1. Thus, while distinct, evolutionary trajectory these combines increased fitness evasion.

Язык: Английский

Процитировано

141
TMPRSS2 is a functional receptor for human coronavirus HKU1 DOI
Nell Saunders, I. Fernández, Cyril Planchais

и другие.

Nature, Год журнала: 2023, Номер 624(7990), С. 207 - 214

Опубликована: Окт. 25, 2023

Язык: Английский

Процитировано

64
SARS-CoV-2 viral persistence in lung alveolar macrophages is controlled by IFN-γ and NK cells DOI Creative Commons
Nicolas Huot, Cyril Planchais,

Pierre Rosenbaum

и другие.

Nature Immunology, Год журнала: 2023, Номер 24(12), С. 2068 - 2079

Опубликована: Ноя. 2, 2023

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) RNA generally becomes undetectable in upper airways after a few days or weeks postinfection. Here we used model of viral infection macaques to address whether SARS-CoV-2 persists the body and which mechanisms regulate its persistence. Replication-competent virus was detected bronchioalveolar lavage (BAL) macrophages beyond 6 months Viral propagation BAL occurred from cell inhibited by interferon-γ (IFN-γ). IFN-γ production strongest NKG2r+CD8+ T cells NKG2Alo natural killer (NK) further increased NK spike protein stimulation. However, impaired with persisting virus. Moreover, also enhanced expression major histocompatibility complex (MHC)-E on macrophages, possibly inhibiting cell-mediated killing. Macaques less mounted adaptive that escaped MHC-E-dependent inhibition. Our findings reveal an interplay between regulated persistence mediated IFN-γ.

Язык: Английский

Процитировано

45
Protective roles and protective mechanisms of neutralizing antibodies against SARS-CoV-2 infection and their potential clinical implications DOI Creative Commons
Endeshaw Chekol Abebe, Tadesse Asmamaw Dejenie

Frontiers in Immunology, Год журнала: 2023, Номер 14

Опубликована: Янв. 19, 2023

Neutralizing antibodies (NAbs) are central players in the humoral immunity that defends body from SARS-CoV-2 infection by blocking viral entry into host cells and neutralizing their biological effects. Even though NAbs primarily work antigens, on some occasions, they may also combat virus escaping neutralization employing several effector mechanisms collaboration with immune like natural killer (NK) phagocytes. Besides prophylactic therapeutic roles, can be used for COVID-19 diagnosis, severity evaluation, prognosis assessment clinical practice. Furthermore, measurement of could have key implications determining individual or herd against SARS-CoV-2, vaccine effectiveness, duration protective response, as well aiding selection suitable individuals who donate convalescent plasma to treat infected people. Despite all these applications NAbs, using them settings present challenges. This review discusses functions, possible potential COVID-19. article highlights challenges solutions associated antibody-based prophylaxis, therapy, vaccination.

Язык: Английский

Процитировано

39
Distinct evolution of SARS-CoV-2 Omicron XBB and BA.2.86/JN.1 lineages combining increased fitness and antibody evasion DOI Creative Commons
Delphine Planas, Isabelle Staropoli, Vincent Michel

и другие.

bioRxiv (Cold Spring Harbor Laboratory), Год журнала: 2023, Номер unknown

Опубликована: Ноя. 21, 2023

The unceasing circulation of SARS-CoV-2 leads to the continuous emergence novel viral sublineages. Here, we isolated and characterized XBB.1, XBB.1.5, XBB.1.9.1, XBB.1.16.1, EG.5.1.1, EG.5.1.3, XBF, BA.2.86.1 JN.1 variants, representing >80% circulating variants in January 2024. XBB subvariants carry few but recurrent mutations spike, whereas harbor >30 additional changes. These replicated IGROV-1 no longer Vero E6 were not markedly fusogenic. They potently infected nasal epithelial cells, with EG.5.1.3 exhibiting highest fitness. Antivirals remained active. Neutralizing antibody (NAb) responses from vaccinees BA.1/BA.2-infected individuals lower compared BA.1, without major differences between variants. An breakthrough infection enhanced NAb against both BA.2.86 displayed affinity ACE2 higher immune evasion properties BA.2.86.1. Thus, while distinct, evolutionary trajectory these combines increased fitness evasion.

Язык: Английский

Процитировано

34
Structural basis of TMPRSS2 zymogen activation and recognition by the HKU1 seasonal coronavirus DOI
I. Fernández, Nell Saunders, S. Duquerroy

и другие.

Cell, Год журнала: 2024, Номер 187(16), С. 4246 - 4260.e16

Опубликована: Авг. 1, 2024

Язык: Английский

Процитировано

15
Three immunizations with Novavax’s protein vaccines increase antibody breadth and provide durable protection from SARS-CoV-2 DOI Creative Commons
Klara Lenart, Rodrigo Arcoverde Cerveira,

Fredrika Hellgren

и другие.

npj Vaccines, Год журнала: 2024, Номер 9(1)

Опубликована: Янв. 20, 2024

Abstract The immune responses to Novavax’s licensed NVX-CoV2373 nanoparticle Spike protein vaccine against SARS-CoV-2 remain incompletely understood. Here, we show in rhesus macaques that immunization with Matrix-M TM adjuvanted vaccines predominantly elicits events local tissues little spillover the periphery. A third dose of an updated based on Gamma (P.1) variant 7 months after two immunizations resulted significant enhancement anti-spike antibody titers and breadth including neutralization forward drift Omicron variants. expanded Spike-specific memory B cell pool, induced somatic hypermutation, increased serum avidity, indicating considerable affinity maturation. Seven immunization, vaccinated animals controlled infection by either WA-1 or P.1 strain, mediated rapid anamnestic T lungs. In conclusion, a adjuvanted, low-dose recombinant significantly improved quality responses, enhanced breadth, provided durable protection challenge.

Язык: Английский

Процитировано

14
A monoclonal antibody targeting a large surface of the receptor binding motif shows pan-neutralizing SARS-CoV-2 activity DOI Creative Commons
Leire de Campos‐Mata, Benjamin Trinité, Andrea Modrego

и другие.

Nature Communications, Год журнала: 2024, Номер 15(1)

Опубликована: Фев. 5, 2024

Abstract Here we report the characterization of 17T2, a SARS-CoV-2 pan-neutralizing human monoclonal antibody isolated from COVID-19 convalescent individual infected during first pandemic wave. 17T2 is class 1 VH1-58/κ3-20 antibody, derived receptor binding domain (RBD)-specific IgA + memory B cell, with broad neutralizing activity against former and new variants, including XBB.1.16 BA.2.86 Omicron subvariants. Consistently, demonstrates in vivo prophylactic therapeutic BA.1.1 infection K18-hACE2 mice. Cryo-electron microscopy reconstruction shows that binds BA.1 spike RBD “up” position blocks motif, as other structurally similar antibodies do, S2E12. Yet, unlike S2E12, retains its all variants tested, probably due to larger contact area. These results highlight impact small structural changes on performance identify potential candidate for future clinical interventions.

Язык: Английский

Процитировано

13
Escape of SARS-CoV-2 Variants KP.1.1, LB.1, and KP.3.3 From Approved Monoclonal Antibodies DOI Creative Commons
Delphine Planas, Isabelle Staropoli, Cyril Planchais

и другие.

Pathogens and Immunity, Год журнала: 2024, Номер 10(1), С. 1 - 11

Опубликована: Сен. 30, 2024

First-generation anti-SARS-CoV-2 monoclonal antibodies (mAbs) used for prophylaxis or therapeutic purposes in immunocompromised patients have been withdrawn because of the emergence resistant Omicron variants. In 2024, 2 novel mAbs, VYD222/Pemivibart and AZD3152/Sipavibart, were approved by health authorities, but their activity against contemporary JN.1 sublineages is poorly characterized.

Язык: Английский

Процитировано

13